Celebrating 50 Years of DSCH: Prognostic Power, Predictive Promise & Patient Progress in Oncology

Marking 50 years of the Danish Society for Cyto- and Histochemistry (DSCH), this Anniversary symposium is more than a scientific meeting: it is a celebration of collaboration, discovery, and the future of biomarkers in oncology.

 

Venue: Auditorium 2, Entrance 44, Rigshospitalet Blegdamsvej 9, 2100 København Ø
Date: 21 May 2026 13.00 – 18.00

Language: English
Moderator: Christian Beltoft Brøchner, MD, PhD, Department of Pathology, Rigshospitalet

 

Program

13:00 – 13:05 | Welcome by DSCH, Kristian Egebjerg, MD, Department of Oncology, Rigshospitalet

13:05 – 13:30 | Block 1: Definitions of biomarkers

  • Clinical examples of prognostic and predictive Biomarkers in Oncology, Morten Mau Sørensen, MD, PhD, Consultant, Department of Oncology Rigshospitalet

13:30 – 15:00 | Block 2: Regulators’ perspectives: New Oncological Drugs in Denmark – Drug-Diagnostic Combinations

  • EMA Regulatory Aspects of Drug and Companion Diagnostic Combinations; Historical Insights, Current Practices, and Future Challenges, Harald Enzmann, MD, MS Bundesinstitut für Arzneimittel und Medizinprodukte, Germany
  • IVDR and Companion Diagnostics from 2022 until now from a Regulatory Perspective, Jeppe Larsen, MS, Head of Medical Devices Division, The Danish Medicines Agency
  • The Role of Biomarkers in Oncology Therapeutic Approvals, Karen Kleberg Hansen, MS, PhD, Department Head of Oncology Medicines, Danish Medicines Council
  • Panel discussion & Q&A

15:00 – 15:20 | Coffee/tea break

15:20 – 16:15 | Block 3: HER2 as a Success Story and the Way Forward

  • Digital Pathology in Denmark: Advances, challenges and future directions, Christian Beltoft Brøchner, MD, PhD, Department of Pathology, Rigshospitalet
  • Algorithms in Action: Digital Tools for Biomarker Evaluation, Jeppe Thagaard, Scientific Director, & Niklas Petersen, New Business Account Executive, Visiopharm
  • Panel discussion & Regulatory reflection: Implementation of automated/AI-based HER2 scoring

16:15 – 16:35 | Coffee/tea break

16:35 – 17:30 | Block 4: Complex Signatures vs Single-Marker Diagnostics

  • Multi-parameter signatures & data integration Frederik Otzen Bagger, MS, PhD, Head of Bioinformatics Genomic Medicine Rigshospitalet
  • Multigene predictive biomarkers in oncology, Ida Kappel Buhl, MD, PhD, CSO AIDA Oncology
  • Panel discussion & Regulatory reflection: How to regulate complex signatures vs single markers

17:35 – 18:00 | Closing remarks. Refreshments will be served

 

Registration is free of charge. Seating is limited, and registration closes on 14 May or once capacity has been reached.

 

On behalf of the Board of DSCH:

Kristian Egebjerg, Karina Hjort,

Tove Kirkegaard Clausen, Filis Necip &

Jan Trøst Jørgensen